NAYA Biosciences Files 8-K/A Amendment
Ticker: IVF · Form: 8-K/A · Filed: Dec 12, 2024 · CIK: 1417926
| Field | Detail |
|---|---|
| Company | Naya Biosciences, INC. (IVF) |
| Form Type | 8-K/A |
| Filed Date | Dec 12, 2024 |
| Risk Level | low |
| Pages | 11 |
| Reading Time | 13 min |
| Key Dollar Amounts | $0.0001, $0.000001, $8,575,833, $3,934,146, $0.93055 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, material-agreement, filing-correction
TL;DR
NAYA Biosciences filed an amendment to an 8-K, correcting/adding info from Oct 11.
AI Summary
NAYA Biosciences, Inc. filed an 8-K/A on December 12, 2024, to amend a previous filing concerning a material definitive agreement and financial statements. The original event date was October 11, 2024. The company, formerly known as INVO Bioscience, Inc., is incorporated in Nevada and headquartered in Sarasota, Florida.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to material information previously disclosed by NAYA Biosciences, Inc.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, not a new material event, and contains no new financial or operational disclosures.
Key Players & Entities
- NAYA Biosciences, Inc. (company) — Registrant
- October 11, 2024 (date) — Earliest event date reported
- December 12, 2024 (date) — Filing date
- INVO Bioscience, Inc. (company) — Former company name
- Sarasota, FL (location) — Principal executive offices
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previously filed 8-K report, specifically addressing Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits).
When was the earliest event reported in the original filing?
The earliest event reported in the original filing was on October 11, 2024.
What was NAYA Biosciences, Inc. formerly known as?
NAYA Biosciences, Inc. was formerly known as INVO Bioscience, Inc.
Where are NAYA Biosciences, Inc.'s principal executive offices located?
NAYA Biosciences, Inc.'s principal executive offices are located at 5582 Broadcast Court, Sarasota, FL 34240.
What is the filing date of this amended report?
This amended report (8-K/A) was filed on December 12, 2024.
Filing Stats: 3,266 words · 13 min read · ~11 pages · Grade level 12.8 · Accepted 2024-12-12 16:47:27
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NAYA The Nasdaq Stock Mar
- $0.000001 — hare of Class A common stock, par value $0.000001 per share, and Class B common stock, pa
- $8,575,833 — ), with a combined principal balance of $8,575,833 converted into the right to receive 669
- $3,934,146 — ebenture issued to FNL in the amount of $3,934,146 was exchanged for a 7.0% Senior Secured
- $0.93055 — y common stock at a conversion price of $0.93055 per share, subject to adjustment as des
- $437,127 — Maturity Date, the Company shall redeem $437,127.24, plus accrued but unpaid interest an
- $3,000,000 — ny receives gross proceeds of more than $3,000,000 from any equity or debt financings (oth
- $500,000 — ) of such gross proceeds, not to exceed $500,000, to the redemption of the principal amo
- $2,000,000 — it received gross proceeds of more than $2,000,000 from any equity or debt financing, it s
- $30,000 — increase its monthly payments by up to $30,000 if the Company closes a private offerin
Filing Documents
- form8-ka.htm (8-K/A) — 84KB
- ex99-2.htm (EX-99.2) — 178KB
- ex99-3.htm (EX-99.3) — 300KB
- ex99-4.htm (EX-99.4) — 184KB
- 0001493152-24-049815.txt ( ) — 1022KB
- naya-20241011.xsd (EX-101.SCH) — 3KB
- naya-20241011_lab.xml (EX-101.LAB) — 34KB
- naya-20241011_pre.xml (EX-101.PRE) — 24KB
- form8-ka_htm.xml (XML) — 4KB
financial statements of NAYA Therapeutics, Inc. as of and for the years ended December 31, 2023 and 2022
financial statements of NAYA Therapeutics, Inc. as of and for the years ended December 31, 2023 and 2022. 99.3 Unaudited financial statements of NAYA Therapeutics, Inc. as of September 30, 2024 and for the nine months ended September 30, 2024 and 2023. 99.4 Pro Forma Financial Statements listed under Item 9.01(b) above. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) *Previously filed. -6-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 12, 2024 NAYA BIOSCIENCES, INC. /s/ Steven Shum Steven Shum Chief Executive Officer -7-